Literature DB >> 34491479

Involvement of anti-inflammatory, antioxidant, and BDNF up-regulating properties in the antipsychotic-like effect of the essential oil of Alpinia zerumbet in mice: a comparative study with olanzapine.

Fernanda Yvelize Ramos de Araújo1, Adriano José Maia Chaves Filho1, Adriana Mary Nunes1, Gersilene Valente de Oliveira1, Patrícia Xavier Lima Gomes1, Germana Silva Vasconcelos1, Jaqueline Carletti1, Manoel Odorico de Moraes2, Maria Elisabete de Moraes3, Silvânia Maria Mendes Vasconcelos1, Francisca Cléa Florenço de Sousa1, David Freitas de Lucena1, Danielle S Macedo4,5.   

Abstract

The current drug therapy for schizophrenia effectively treats acute psychosis and its recurrence; however, this mental disorder's cognitive and negative symptoms are still poorly controlled. Antipsychotics present important side effects, such as weight gain and extrapyramidal effects. The essential oil of Alpinia zerumbet (EOAZ) leaves presents potential antipsychotic properties that need further preclinical investigation. Here, we determined EAOZ effects in preventing and reversing schizophrenia-like symptoms (positive, negative, and cognitive) induced by ketamine (KET) repeated administration in mice and putative neurobiological mechanisms related to this effect. We conducted the behavioral evaluations of prepulse inhibition of the startle reflex (PPI), social interaction, and working memory (Y-maze task), and verified antioxidant (GSH, nitrite levels), anti-inflammatory [interleukin (IL)-6], and neurotrophic [brain-derived neurotrophic factor (BDNF)] effects of this oil in hippocampal tissue. The atypical antipsychotic olanzapine (OLZ) was used as standard drug therapy. EOAZ, similarly to OLZ, prevented and reversed most KET-induced schizophrenia-like behavioral alterations, i.e., sensorimotor gating deficits and social impairment. EOAZ had a modest effect on the prevention of KET-associated working memory deficit. Compared to OLZ, EOAZ showed a more favorable side effects profile, inducing less cataleptic and weight gain changes. EOAZ efficiently protected the hippocampus against KET-induced oxidative imbalance, IL-6 increments, and BDNF impairment. In conclusion, our data add more mechanistic evidence for the anti-schizophrenia effects of EOAZ, based on its antioxidant, anti-inflammatory, and BDNF up-regulating actions. The absence of significant side effects observed in current antipsychotic drug therapy seems to be an essential benefit of the oil.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Alpinia zerumbet; Anti-inflammatory effects; Antipsychotic effects; Extrapyramidal side effects; Ketamine model; Schizophrenia

Mesh:

Substances:

Year:  2021        PMID: 34491479     DOI: 10.1007/s11011-021-00821-5

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  63 in total

Review 1.  Regional dissociations within the hippocampus--memory and anxiety.

Authors:  D M Bannerman; J N P Rawlins; S B McHugh; R M J Deacon; B K Yee; T Bast; W-N Zhang; H H J Pothuizen; J Feldon
Journal:  Neurosci Biobehav Rev       Date:  2004-05       Impact factor: 8.989

2.  Morin Attenuates Neurochemical Changes and Increased Oxidative/Nitrergic Stress in Brains of Mice Exposed to Ketamine: Prevention and Reversal of Schizophrenia-Like Symptoms.

Authors:  Benneth Ben-Azu; Adegbuyi Oladele Aderibigbe; Aya-Ebi Okubo Eneni; Abayomi Mayowa Ajayi; Solomon Umukoro; Ezekiel O Iwalewa
Journal:  Neurochem Res       Date:  2018-06-28       Impact factor: 3.996

Review 3.  Sex differences in schizophrenia.

Authors:  Kathryn M Abel; Richard Drake; Jill M Goldstein
Journal:  Int Rev Psychiatry       Date:  2010

4.  Probable mechanisms involved in the antipsychotic-like activity of morin in mice.

Authors:  Benneth Ben-Azu; Adegbuyi Oladele Aderibigbe; Itivere Adrian Omogbiya; Abayomi Mayowa Ajayi; Olatunde Owoeye; Elizabeth Toyin Olonode; Ezekiel O Iwalewa
Journal:  Biomed Pharmacother       Date:  2018-06-20       Impact factor: 6.529

5.  Cannabinoid receptors on peripheral leukocytes from patients with schizophrenia: Evidence for defective immunomodulatory mechanisms.

Authors:  Salvina Maria de Campos-Carli; Marcio Sobreira Araújo; Amanda Cardoso de Oliveira Silveira; Vitor Bortolo de Rezende; Natalia Pessoa Rocha; Rodrigo Ferretjans; Rafael Ribeiro-Santos; Andrea Teixeira-Carvalho; Olindo Assis Martins-Filho; Michael Berk; João Vinícius Salgado; Antonio Lucio Teixeira
Journal:  J Psychiatr Res       Date:  2016-12-03       Impact factor: 4.791

6.  Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity.

Authors:  Axel Becker; Gisela Grecksch
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-12       Impact factor: 5.067

7.  Hippocampal-dorsolateral prefrontal coupling as a species-conserved cognitive mechanism: a human translational imaging study.

Authors:  Florian Bähner; Charmaine Demanuele; Janina Schweiger; Martin F Gerchen; Vera Zamoscik; Kai Ueltzhöffer; Tim Hahn; Patric Meyer; Herta Flor; Daniel Durstewitz; Heike Tost; Peter Kirsch; Michael M Plichta; Andreas Meyer-Lindenberg
Journal:  Neuropsychopharmacology       Date:  2015-01-12       Impact factor: 7.853

8.  Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice.

Authors:  Benneth Ben-Azu; Adegbuyi Oladele Aderibigbe; Abayomi Mayowa Ajayi; Aya-Ebi Okubo Eneni; Solomon Umukoro; Ezekiel O Iwalewa
Journal:  Brain Res Bull       Date:  2018-03-13       Impact factor: 4.077

9.  β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice.

Authors:  Amine Bahi; Shamma Al Mansouri; Elyazia Al Memari; Mouza Al Ameri; Syed M Nurulain; Shreesh Ojha
Journal:  Physiol Behav       Date:  2014-06-13

10.  Sex differences in the risk of schizophrenia: evidence from meta-analysis.

Authors:  Andre Aleman; René S Kahn; Jean-Paul Selten
Journal:  Arch Gen Psychiatry       Date:  2003-06
View more
  2 in total

1.  Taurine, an essential β-amino acid insulates against ketamine-induced experimental psychosis by enhancement of cholinergic neurotransmission, inhibition of oxidative/nitrergic imbalances, and suppression of COX-2/iNOS immunoreactions in mice.

Authors:  Benneth Ben-Azu; Olusegun G Adebayo; Thiophilus Aghogho Jarikre; Mega O Oyovwi; Kesiena Emmanuel Edje; Itivere Adrian Omogbiya; Anthony T Eduviere; Emuesiri Goodies Moke; Bienose S Chijioke; Onyebuchi S Odili; Osemudiame P Omondiabge; Aghogho Oyovbaire; Daniel T Esuku; Esther O Ozah; Kelvin Japhet
Journal:  Metab Brain Dis       Date:  2022-09-03       Impact factor: 3.655

Review 2.  Advantages and Limitations of Animal Schizophrenia Models.

Authors:  Magdalena Białoń; Agnieszka Wąsik
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.